EMA Backs Etcamah for ESR1+ Breast Cancer

Key Takeaways

• On 21 May 2026, CHMP recommended granting marketing authorisation for Etcamah (camizestrant) in ESR1-mutated ER-positive, HER2-negative locally advanced or metastatic breast cancer.
• The applicant is AstraZeneca AB; planned presentation is 75 mg film-coated tablets (ATC L02BA05; procedure EMEA/H/C/006494).
• Benefit cited by EMA is improved progression-free survival when patients switch to camizestrant plus a CDK4/6 inhibitor after ESR1 mutation detection on first-line aromatase inhibitor plus CDK4/6 therapy.
• Common side effects listed with CDK4/6 combination include neutropenia, visual effects, infections, anaemia, diarrhoea, nausea, fatigue, bradycardia, and leukopenia.

Etcamah CHMP opinion at a glance

Field	Detail
Product / INN	Etcamah / camizestrant
Applicant	AstraZeneca AB
CHMP opinion date	21 May 2026 (positive)
Proposed use	ER+/HER2− locally advanced or metastatic breast cancer with ESR1 mutation, with CDK4/6 inhibitor
Formulation	75 mg film-coated tablets
EU status	Opinion adopted; Commission decision pending

What exactly did CHMP recommend?

EMA’s Etcamah medicine page states that on 21 May 2026 the Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorisation for Etcamah for ER-positive, HER2-negative locally advanced or metastatic breast cancer in patients with ESR1 gene mutations, according to EMA's Etcamah medicine overview.

Camizestrant is described as an anti-oestrogen endocrine therapy and an oral next-generation selective oestrogen receptor degrader (ngSERD) that fully antagonises the oestrogen receptor. EMA says it blocks ERα encoded by both wild-type and mutated ESR1 and induces proteasome-dependent ERα degradation without agonising ERα.

The opinion status on the EMA page remains “Positive,” with steps still shown through European Commission decision. That sequencing matters for hospital formulary planners: CHMP support is not the same as a granted EU marketing authorisation.

How is the indication written in the summary of opinion?

The CHMP summary of positive opinion (EMA/114517/2026) restates the 21 May 2026 recommendation and sets out the full proposed indication, per CHMP's summary of positive opinion for Etcamah.

Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of an ESR1 mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor. Biomarker-based patient selection is referenced to SmPC sections 4.2 and 5.1.

In pre- or peri-menopausal women and in men, Etcamah plus a CDK4/6 inhibitor should be combined with an LHRH agonist or antagonist. Treatment should be initiated and supervised by a physician experienced in anticancer medicines.

What clinical benefit and risks did EMA highlight?

EMA says the benefit of Etcamah plus a CDK4/6 inhibitor is improved progression-free survival when patients are switched to camizestrant after ESR1 mutation detection while on first-line aromatase inhibitor plus CDK4/6 therapy, compared with continuing the same aromatase inhibitor and CDK4/6 combination.

The most common side effects listed with the CDK4/6 combination are neutropenia, visual effects, infections, anaemia, diarrhoea, nausea, fatigue, bradycardia, and leukopenia. Detailed recommendations will appear in the SmPC after Commission authorisation, EMA notes.

The summary of opinion also reminds readers that positive opinions are published without prejudice to the Commission decision, normally issued 67 days from adoption of the opinion.

Where does Etcamah sit in the May 2026 CHMP package?

EMA’s CHMP meeting highlights for 18–21 May 2026, published 22 May 2026, say the committee recommended eight medicines for approval and listed Etcamah among them for adults with locally advanced or metastatic breast cancer with a specific ESR1 gene mutation, according to EMA's CHMP 18-21 May 2026 meeting highlights.

That same meeting also recommended indication extensions for several oncology products, including Enhertu and Trodelvy. Those extensions are separate regulatory actions; this article’s primary story remains the initial Etcamah opinion because it is a new active-substance breast-cancer recommendation with a dedicated EPAR opinion page and SMOP.

For EU launch teams, the near-term clock is Commission decision timing, SmPC publication in official languages, and national pricing or HTA steps after authorisation—not the trade-press “glance” framing of April–June breast-cancer news.

What remains unproven or still pending?

Allowlisted EMA pages confirm the CHMP opinion, proposed indication language, formulation, applicant, and high-level benefit/risk statements. They do not, in the materials cited here, publish detailed Kaplan–Meier curves, hazard ratios, or full trial identifiers on the public Etcamah overview text. Those numbers should be taken from the eventual EPAR/SmPC, not invented from secondary coverage.

Until the European Commission grants marketing authorisation, Etcamah is not an authorised EU medicine. Hospitals and payers should treat current status as CHMP-positive, Commission-pending.

Related NovaPharma coverage: Vanda EMA orphan positive opinion, PRAC June 2026 highlights, and EU Commission and EMA 2026 drug report.

Frequently Asked Questions

Primary Sources

1. EMA: Etcamah (camizestrant) medicine overview / CHMP opinion
2. EMA: CHMP summary of positive opinion for Etcamah (EMA/114517/2026)
3. EMA: CHMP meeting highlights 18-21 May 2026